Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Human PAH is characterized by a pattern of lipid-related insulin resistance.

Hemnes AR, Luther JM, Rhodes CJ, Burgess JP, Carlson J, Fan R, Fessel JP, Fortune N, Gerszten RE, Halliday SJ, Hekmat R, Howard L, Newman JH, Niswender KD, Pugh ME, Robbins IM, Sheng Q, Shibao CA, Shyr Y, Sumner S, Talati M, Wharton J, Wilkins MR, Ye F, Yu C, West J, Brittain EL.

JCI Insight. 2019 Jan 10;4(1). pii: 123611. doi: 10.1172/jci.insight.123611. [Epub ahead of print]

2.

Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.

Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, Langleben D, Lumens J, Naeije R.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801900. doi: 10.1183/13993003.01900-2018. Print 2019 Jan.

3.

Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy.

Brittain EL, Talati M, Fortune N, Agrawal V, Meoli DF, West J, Hemnes AR.

Pulm Circ. 2019 Jan-Mar;9(1):2045894018817741. doi: 10.1177/2045894018817741. Epub 2018 Nov 19.

4.

Reduced free-living activity levels in pulmonary arterial hypertension patients.

Halliday SJ, Shi H, Brittain EL, Hemnes AR.

Pulm Circ. 2019 Jan-Mar;9(1):2045894018814182. doi: 10.1177/2045894018814182. Epub 2018 Nov 13.

PMID:
30419794
5.

Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice: Implications for Pulmonary Hypertension Classification.

Hemnes AR, Opotowsky AR, Assad TR, Xu M, Doss LN, Farber-Eger E, Wells QS, Brittain EL.

Chest. 2018 Nov;154(5):1099-1107. doi: 10.1016/j.chest.2018.08.1033. Epub 2018 Aug 24.

PMID:
30148982
6.

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension.

Halliday SJ, Xu M, Thayer TE, Mosley JD, Sheng Q, Ye F, Farber-Eger EH, Pugh ME, Robbins IR, Assad TR, West JD, Brittain EL, Hemnes AR.

Pulm Circ. 2018 Oct-Dec;8(4):2045894018800544. doi: 10.1177/2045894018800544. Epub 2018 Aug 24.

7.

Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.

Lahm T, Douglas IS, Archer SL, Bogaard HJ, Chesler NC, Haddad F, Hemnes AR, Kawut SM, Kline JA, Kolb TM, Mathai SC, Mercier O, Michelakis ED, Naeije R, Tuder RM, Ventetuolo CE, Vieillard-Baron A, Voelkel NF, Vonk-Noordegraaf A, Hassoun PM; American Thoracic Society Assembly on Pulmonary Circulation.

Am J Respir Crit Care Med. 2018 Aug 15;198(4):e15-e43. doi: 10.1164/rccm.201806-1160ST.

PMID:
30109950
8.

Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement.

O'Leary JM, Assad TR, Xu M, Farber-Eger E, Wells QS, Hemnes AR, Brittain EL.

J Am Heart Assoc. 2018 Jun 30;7(13). pii: e009362. doi: 10.1161/JAHA.118.009362.

9.

A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension.

Hemnes AR, Rathinasabapathy A, Austin EA, Brittain EL, Carrier EJ, Chen X, Fessel JP, Fike CD, Fong P, Fortune N, Gerszten RE, Johnson JA, Kaplowitz M, Newman JH, Piana R, Pugh ME, Rice TW, Robbins IM, Wheeler L, Yu C, Loyd JE, West J.

Eur Respir J. 2018 Jun 21;51(6). pii: 1702638. doi: 10.1183/13993003.02638-2017. Print 2018 Jun.

PMID:
29903860
10.

Using Omics to Understand and Treat Pulmonary Vascular Disease.

Hemnes AR.

Front Med (Lausanne). 2018 May 24;5:157. doi: 10.3389/fmed.2018.00157. eCollection 2018. Review.

11.

Autonomic Nervous System in Pulmonary Arterial Hypertension: Time to Rest and Digest.

Hemnes AR, Brittain EL.

Circulation. 2018 Feb 27;137(9):925-927. doi: 10.1161/CIRCULATIONAHA.117.032355. No abstract available.

12.

Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension.

Yang BQ, Assad TR, O'Leary JM, Xu M, Halliday SJ, D'Amico RW, Farber-Eger EH, Wells QS, Hemnes AR, Brittain EL.

Pulm Circ. 2018 Apr-Jun;8(2):2045894018764273. doi: 10.1177/2045894018764273. Epub 2018 Feb 26.

13.

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174. doi: 10.1164/rccm.201710-2093PP. No abstract available.

PMID:
29425462
14.

Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension.

Whitaker ME, Nair V, Sinari S, Dherange PA, Natarajan B, Trutter L, Brittain EL, Hemnes AR, Austin ED, Patel K, Black SM, Garcia JGN, Yuan Md PhD JX, Vanderpool RR, Rischard F, Makino A, Bedrick EJ, Desai AA.

Am J Med. 2018 Jun;131(6):702.e7-702.e13. doi: 10.1016/j.amjmed.2017.12.046. Epub 2018 Feb 5.

PMID:
29421689
15.

Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.

Hemnes AR, Humbert M.

Eur Respir Rev. 2017 Dec 20;26(146). pii: 170093. doi: 10.1183/16000617.0093-2017. Print 2017 Dec 31. Review.

16.

The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension.

Meoli DF, Su YR, Brittain EL, Robbins IM, Hemnes AR, Monahan K.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217745019. doi: 10.1177/2045893217745019. Epub 2017 Dec 18.

17.

PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics.

Hemnes AR, Beck GJ, Newman JH, Abidov A, Aldred MA, Barnard J, Berman Rosenzweig E, Borlaug BA, Chung WK, Comhair SAA, Erzurum SC, Frantz RP, Gray MP, Grunig G, Hassoun PM, Hill NS, Horn EM, Hu B, Lempel JK, Maron BA, Mathai SC, Olman MA, Rischard FP, Systrom DM, Tang WHW, Waxman AB, Xiao L, Yuan JX, Leopold JA; PVDOMICS Study Group.

Circ Res. 2017 Oct 27;121(10):1136-1139. doi: 10.1161/CIRCRESAHA.117.311737. No abstract available.

18.

Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension.

Assad TR, Maron BA, Robbins IM, Xu M, Huang S, Harrell FE, Farber-Eger EH, Wells QS, Choudhary G, Hemnes AR, Brittain EL.

JAMA Cardiol. 2017 Dec 1;2(12):1361-1368. doi: 10.1001/jamacardio.2017.3882.

19.

Reply: Tidal Carbon Dioxide as a Prognostic Feature in Inoperable Chronic Thromboembolic Pulmonary Hypertension.

Welch CE, Hemnes AR.

Ann Am Thorac Soc. 2017 Oct;14(10):1604-1605. doi: 10.1513/AnnalsATS.201707-621LE. No abstract available.

PMID:
28806530
20.

Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Chen X, Austin ED, Talati M, Fessel JP, Farber-Eger EH, Brittain EL, Hemnes AR, Loyd JE, West J.

Eur Respir J. 2017 Aug 3;50(2). pii: 1602337. doi: 10.1183/13993003.02337-2016. Print 2017 Aug.

21.

Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension.

Trammell AW, Talati M, Blackwell TR, Fortune NL, Niswender KD, Fessel JP, Newman JH, West JD, Hemnes AR.

Pulm Circ. 2017 Jul-Sep;7(3):624-634. doi: 10.1086/689908. Epub 2017 Aug 7.

22.

Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension.

Egnatchik RA, Brittain EL, Shah AT, Fares WH, Ford HJ, Monahan K, Kang CJ, Kocurek EG, Zhu S, Luong T, Nguyen TT, Hysinger E, Austin ED, Skala MC, Young JD, Roberts LJ 2nd, Hemnes AR, West J, Fessel JP.

Pulm Circ. 2017 Feb 1;7(1):186-199. doi: 10.1086/690236. eCollection 2017 Mar.

23.

Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes.

O'Leary JM, Assad TR, Xu M, Birdwell KA, Farber-Eger E, Wells QS, Hemnes AR, Brittain EL.

Pulm Circ. 2017 Jul-Sep;7(3):674-683. doi: 10.1177/2045893217716108. Epub 2017 Jun 29.

24.

Identifying "super responders" in pulmonary arterial hypertension.

Halliday SJ, Hemnes AR.

Pulm Circ. 2017 Apr-Jun;7(2):300-311. doi: 10.1177/2045893217697708. Epub 2017 May 30.

25.

Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction.

Gaskill CF, Carrier EJ, Kropski JA, Bloodworth NC, Menon S, Foronjy RF, Taketo MM, Hong CC, Austin ED, West JD, Means AL, Loyd JE, Merryman WD, Hemnes AR, De Langhe S, Blackwell TS, Klemm DJ, Majka SM.

J Clin Invest. 2017 Jun 1;127(6):2262-2276. doi: 10.1172/JCI88629. Epub 2017 May 2.

26.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.

27.

Echocardiographic Pulmonary Artery Systolic Pressure in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Associations With Race and Metabolic Dysregulation.

Brittain EL, Nwabuo C, Xu M, Gupta DK, Hemnes AR, Moreira HT, De Vasconcellos HD, Terry JG, Carr JJ, Lima JA.

J Am Heart Assoc. 2017 Mar 30;6(4). pii: e005111. doi: 10.1161/JAHA.116.005111.

28.

End-Tidal Carbon Dioxide as a Prognostic Feature in Pulmonary Arterial Hypertension.

Welch CE, Brittain EL, Newman AL, Robbins IM, Pugh ME, Newman JH, Hemnes AR.

Ann Am Thorac Soc. 2017 Jun;14(6):896-902. doi: 10.1513/AnnalsATS.201612-951OC.

PMID:
28345964
29.

Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease.

Gaskill C, Marriott S, Pratap S, Menon S, Hedges LK, Fessel JP, Kropski JA, Ames D, Wheeler L, Loyd JE, Hemnes AR, Roop DR, Klemm DJ, Austin ED, Majka SM.

Pulm Circ. 2016 Dec;6(4):483-497. doi: 10.1086/688314.

30.

Rebuttal From Dr Hemnes.

Hemnes AR.

Chest. 2017 Jul;152(1):20-21. doi: 10.1016/j.chest.2016.12.010. Epub 2017 Jan 5. No abstract available.

PMID:
28065564
31.

COUNTERPOINT: Should Wireless Pulmonary Artery Hemodynamic Monitoring Be Used to Monitor Patients With Pulmonary Hypertension? No.

Hemnes AR.

Chest. 2017 Jul;152(1):16-18. doi: 10.1016/j.chest.2016.12.009. Epub 2017 Jan 5. No abstract available.

PMID:
28065561
32.

Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension.

Assad TR, Hemnes AR, Larkin EK, Glazer AM, Xu M, Wells QS, Farber-Eger EH, Sheng Q, Shyr Y, Harrell FE, Newman JH, Brittain EL.

J Am Coll Cardiol. 2016 Dec 13;68(23):2525-2536. doi: 10.1016/j.jacc.2016.09.942.

33.

Hemodynamic evidence of vascular remodeling in combined post- and precapillary pulmonary hypertension.

Assad TR, Brittain EL, Wells QS, Farber-Eger EH, Halliday SJ, Doss LN, Xu M, Wang L, Harrell FE, Yu C, Robbins IM, Newman JH, Hemnes AR.

Pulm Circ. 2016 Sep;6(3):313-21. doi: 10.1086/688516.

34.

The difficult diagnosis of pulmonary vascular disease in heart failure.

Naeije R, Hemnes AR.

Eur Respir J. 2016 Aug;48(2):308-10. doi: 10.1183/13993003.00789-2016. No abstract available.

35.

Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing.

Austin ED, West J, Loyd JE, Hemnes AR.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):23-31. doi: 10.1164/rccm.201605-0905PP. No abstract available.

36.

Update on chronic thromboembolic pulmonary hypertension.

Robbins IM, Pugh ME, Hemnes AR.

Trends Cardiovasc Med. 2017 Jan;27(1):29-37. doi: 10.1016/j.tcm.2016.05.010. Epub 2016 May 25. Review.

PMID:
27345156
37.

Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload.

West JD, Voss BM, Pavliv L, de Caestecker M, Hemnes AR, Carrier EJ.

Pulm Circ. 2016 Jun;6(2):211-23. doi: 10.1086/686140.

38.

Severity of pulmonary hypertension and obesity are not associated with worse functional outcomes after pulmonary thromboendarterectomy.

Matthews DT, Le CN, Robbins IM, Petracek MR, Pugh ME, Brittain EL, Hemnes AR.

Pulm Circ. 2016 Jun;6(2):174-80. doi: 10.1086/685736.

39.

Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Matthews DT, Hemnes AR.

Pulm Circ. 2016 Jun;6(2):145-54. doi: 10.1086/686011. Review.

40.

Women's Health and Lung Development and Disease.

Kocurek EG, Hemnes AR.

Obstet Gynecol Clin North Am. 2016 Jun;43(2):307-23. doi: 10.1016/j.ogc.2016.01.003. Review.

PMID:
27212094
41.

Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.

Talati MH, Brittain EL, Fessel JP, Penner N, Atkinson J, Funke M, Grueter C, Jerome WG, Freeman M, Newman JH, West J, Hemnes AR.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):719-28. doi: 10.1164/rccm.201507-1444OC.

42.

Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension.

Brittain EL, Talati M, Fessel JP, Zhu H, Penner N, Calcutt MW, West JD, Funke M, Lewis GD, Gerszten RE, Hamid R, Pugh ME, Austin ED, Newman JH, Hemnes AR.

Circulation. 2016 May 17;133(20):1936-44. doi: 10.1161/CIRCULATIONAHA.115.019351. Epub 2016 Mar 22.

43.

Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension.

Hemnes AR, Zhao M, West J, Newman JH, Rich S, Archer SL, Robbins IM, Blackwell TS, Cogan J, Loyd JE, Zhao Z, Gaskill C, Jetter C, Kropski JA, Majka SM, Austin ED.

Am J Respir Crit Care Med. 2016 Aug 15;194(4):464-75. doi: 10.1164/rccm.201508-1678OC.

44.

Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction.

Mar PL, Nwazue V, Black BK, Biaggioni I, Diedrich A, Paranjape SY, Loyd JE, Hemnes AR, Robbins IM, Robertson D, Raj SR, Austin ED.

Chest. 2016 May;149(5):1252-60. doi: 10.1016/j.chest.2015.11.015. Epub 2016 Jan 13.

45.

Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension.

Lewis GD, Ngo D, Hemnes AR, Farrell L, Domos C, Pappagianopoulos PP, Dhakal BP, Souza A, Shi X, Pugh ME, Beloiartsev A, Sinha S, Clish CB, Gerszten RE.

J Am Coll Cardiol. 2016 Jan 19;67(2):174-189. doi: 10.1016/j.jacc.2015.10.072.

46.

Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis.

Bryant AJ, Robinson LJ, Moore CS, Blackwell TR, Gladson S, Penner NL, Burman A, McClellan LJ, Polosukhin VV, Tanjore H, McConaha ME, Gleaves LA, Talati MA, Hemnes AR, Fessel JP, Lawson WE, Blackwell TS, West JD.

Pulm Circ. 2015 Dec;5(4):681-90. doi: 10.1086/683811.

47.

Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension.

Bryant AJ, Carrick RP, McConaha ME, Jones BR, Shay SD, Moore CS, Blackwell TR, Gladson S, Penner NL, Burman A, Tanjore H, Hemnes AR, Karwandyar AK, Polosukhin VV, Talati MA, Dong HJ, Gleaves LA, Carrier EJ, Gaskill C, Scott EW, Majka SM, Fessel JP, Haase VH, West JD, Blackwell TS, Lawson WE.

Am J Physiol Lung Cell Mol Physiol. 2016 Feb 1;310(3):L249-62. doi: 10.1152/ajplung.00258.2015. Epub 2015 Dec 4.

48.

Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism.

Chen X, Talati M, Fessel JP, Hemnes AR, Gladson S, French J, Shay S, Trammell A, Phillips JA, Hamid R, Cogan JD, Dawson EP, Womble KE, Hedges LK, Martinez EG, Wheeler LA, Loyd JE, Majka SJ, West J, Austin ED.

Circulation. 2016 Jan 5;133(1):82-97. doi: 10.1161/CIRCULATIONAHA.115.016133. Epub 2015 Oct 20.

49.

The Diastolic Pressure Gradient Does Not-and Should Not-Predict Outcomes.

Brittain EL, Assad TR, Hemnes AR, Newman JH.

JACC Heart Fail. 2015 Oct;3(10):845. doi: 10.1016/j.jchf.2015.06.008. No abstract available.

50.

Right ventricular protein expression profile in end-stage heart failure.

Su YR, Chiusa M, Brittain E, Hemnes AR, Absi TS, Lim CC, Di Salvo TG.

Pulm Circ. 2015 Sep;5(3):481-97. doi: 10.1086/682219.

Supplemental Content

Loading ...
Support Center